Aucuba-001
Alzheimer's Disease
Key Facts
About Aucuba Sciences
Aucuba Sciences is a private, preclinical-stage biotech focused on developing transformative therapies for neurodegenerative diseases by targeting the fundamental biology of aging. The company's core technology platform is built on research into cellular senescence and proteostasis, aiming to develop disease-modifying treatments rather than symptomatic relief. With a strong scientific foundation and experienced leadership team, Aucuba is working to advance its lead candidate toward clinical development while exploring broader applications of its aging-focused platform. The company represents a novel approach in the competitive neurodegeneration space, seeking to alter disease progression rather than merely manage symptoms.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |